Literature DB >> 27568473

Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.

Marzieh Salehi1, David A D'Alessio2.   

Abstract

Bariatric surgery is the most effective treatment for obesity and diabetes. The 2 most commonly performed weight-loss procedures, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy, improve glycemic control in patients with type 2 diabetes independent of weight loss. One of the early hypotheses raised to explain the immediate antidiabetic effect of RYGB was that rapid delivery of nutrients from the stomach pouch into the distal small intestine enhances enteroinsular signaling to promote insulin signaling. Given the tenfold increase in postmeal glucagon-like peptide-1 (GLP-1) response compared to unchanged integrated levels of postprandial glucose-dependent insulinotropic peptide after RYGB, enhanced meal-induced insulin secretion after this procedure was thought to be the result of elevated glucose and GLP-1 levels. In this contribution to the larger point-counterpoint debate about the role of GLP-1 after bariatric surgery, most of the focus will be on RYGB.
Copyright © 2016 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; GLP-1; Gastric bypass surgery; Hyperinsulinemia; Hypoglycemia

Mesh:

Substances:

Year:  2016        PMID: 27568473      PMCID: PMC5002889          DOI: 10.1016/j.soard.2016.05.008

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  47 in total

1.  Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity.

Authors:  P R Schauer; S Ikramuddin; W Gourash; R Ramanathan; J Luketich
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

2.  Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover.

Authors:  Juris J Meier; Alexandra E Butler; Ryan Galasso; Peter C Butler
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

3.  Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia.

Authors:  M E Patti; G McMahon; E C Mun; A Bitton; J J Holst; J Goldsmith; D W Hanto; M Callery; R Arky; V Nose; S Bonner-Weir; A B Goldfine
Journal:  Diabetologia       Date:  2005-09-30       Impact factor: 10.122

Review 4.  beta-cell function in obesity: effects of weight loss.

Authors:  Ele Ferrannini; Stefania Camastra; Amalia Gastaldelli; Anna Maria Sironi; Andrea Natali; Elza Muscelli; Geltrude Mingrone; Andrea Mari
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

5.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.

Authors:  J Schirra; M Nicolaus; R Roggel; M Katschinski; M Storr; H J Woerle; B Göke
Journal:  Gut       Date:  2005-06-28       Impact factor: 23.059

6.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.

Authors:  Geoffrey J Service; Geoffrey B Thompson; F John Service; James C Andrews; Maria L Collazo-Clavell; Ricardo V Lloyd
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

7.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Authors:  Tina Vilsbøll; Thure Krarup; Sten Madsbad; Jens J Holst
Journal:  Regul Pept       Date:  2003-07-15

8.  Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal.

Authors:  A B Goldfine; E C Mun; E Devine; R Bernier; M Baz-Hecht; D B Jones; B E Schneider; J J Holst; M E Patti
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

9.  Improved beta-cell function after standardized weight reduction in severely obese subjects.

Authors:  Marie Guldstrand; Bo Ahrén; Ulf Adamson
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-03       Impact factor: 4.310

10.  Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.

Authors:  Blandine Laferrère; Stanley Heshka; Krystle Wang; Yasmin Khan; James McGinty; Julio Teixeira; Allison B Hart; Blanca Olivan
Journal:  Diabetes Care       Date:  2007-04-06       Impact factor: 19.112

View more
  5 in total

1.  Metabolic Surgery Comparing Sleeve Gastrectomy with Jejunal Bypass and Roux-en-Y Gastric Bypass in Type 2 Diabetic Patients After 3 Years.

Authors:  Matías Sepúlveda; Munir Alamo; Yudith Preiss; Juan P Valderas
Journal:  Obes Surg       Date:  2018-11       Impact factor: 4.129

Review 2.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

3.  Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.

Authors:  Jennifer Lee; Jacqueline Koehler; Bernardo Yusta; Jasmine Bahrami; Dianne Matthews; Mahroukh Rafii; Paul B Pencharz; Daniel J Drucker
Journal:  Mol Metab       Date:  2017-01-17       Impact factor: 7.422

4.  Roux-en-Y gastric bypass alters intestinal glucose transport in the obese Zucker rat.

Authors:  Qinghe Meng; Derek M Culnan; Tamer Ahmed; Mingjie Sun; Robert N Cooney
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-11       Impact factor: 6.055

Review 5.  Oral Processing, Satiation and Obesity: Overview and Hypotheses.

Authors:  Arnold Slyper
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-26       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.